Novel xCELLigence Study of Acinetobacter baumannii Biofilms Receives Award
SAN DIEGO, Calif. (PRWEB) July 17, 2018 -- By using the xCELLigence instrument to monitor the attachment and growth of Acinetobacter baumannii in real-time, University of South Florida graduate student Jessie Adams has discovered key genes/proteins that enable this pathogen to persist in the surface-attached biofilm state. On the basis of the novelty and impact of this work, which Adams will present at the American Society of Microbiology conference on Biofilms (October 7-11 in Washington DC), she was selected as the sole recipient of the ACEA Biosciences Travel Award for Spring 2018.
A major cause of hospital-acquired wound related and respiratory infections, A. baumannii displays broad antibiotic resistance and is currently listed as #1 on the World Health Organization’s list of critical pathogens. In the majority of A. baumannii infections the bacterium grows in a biofilm state, where the cells are enmeshed in an extensive network of secreted polymeric molecules that afford the pathogen chemical and physical protection. Despite the clinical importance of A. baumannii biofilm infections, little has been known about the genes that make the biofilm lifestyle possible.
Ms. Adams has used a transposon library to generate a vast array of A. baumannii mutants, the attachment and growth kinetics of which she has quantified using the automated, label-free xCELLigence assay. Adams stated that the xCELLigence instrument is playing “a major role in my research, coupling the standard endpoint biofilm assay (crystal violet staining) with a real-time analysis of the attachment of the lead mutants that show distinct phenotypes. For the data to be presented at this conference, over 60 mutants have already been screened.” She went on to say “We will be continuing our screen and utilizing this invaluable assay to screen over 300 mutants to get a true understanding of the genes responsible for regulating biofilm formation in A. baumannii. Without the xCELLigence system, this project would not be possible as we are already finding unique phenotypes that have never been seen before in A. baumannii. To our knowledge, there is only a handful of genes proven to regulate biofilm formation and even in the earliest stages of this project we have been able to identify a plethora of novel regulators thanks to this unique system.” To view Ms. Adams’ research poster, click here.
To learn more about ACEA’s Travel Award, see profiles of past winners, or download the application form for future funding cycles, click here. In addition to the travel award, ACEA also provides an xCELLigence Research Grant, which provides the grant winner access to RTCA technology for six months. To learn more, click here.
About xCELLigence® Real Time Cell Analysis (RTCA)
ACEA’s xCELLigence RTCA instruments are being used in both academia and industry for life science applications ranging from cancer immunotherapy, bacterial biofilms, vaccine development and cardiotoxicity testing. With the xCELLigence technology, scientists can non-invasively monitor the behavior of cells by quantifying cell proliferation, morphology change, and attachment quality in a label-free, real-time manner.
About ACEA Biosciences
Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. ACEA’s xCELLigence® Real-Time Cell Analysis instruments and NovoCyte® flow cytometer are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,500 instruments have been placed globally, and have been used in more than 1,800 peer-reviewed publications, which can be viewed in a searchable library.
For more information visit http://www.aceabio.com.
Follow on LinkedIn, Twitter, and Facebook.
For further information please contact:
ACEA Biosciences, Inc.
Dr. Jeff Xue
Phone: 1-858-299-8023
email: jxue(at)aceabio(dot)com
Jeff Xue, Ph.D., ACEA Biosciences, Inc., http://www.aceabio.com, +1 8587240928 Ext: 3075, [email protected]
Share this article